Evidence map›Paper›PMID 35663788›Full record

ArticleInternational journal of pediatrics & adolescent medicine2022

Liver disease in cystic fibrosis patients in a tertiary care center in Saudi Arabia.

Hanaa Banjar, Najlaa AbdulAziz, Jumana Khader, Firas Ghomraoui, AbdulAziz Alansari, Abdulaziz Al-Hoshan, Sara AlKaf, Wajeeh Aldakheel

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pediatrics & adolescent medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hanaa BanjarDepartment of Pediatrics, King Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia.
Najlaa AbdulAzizDepartment of Pediatrics, King Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia.
Jumana KhaderCollege of Medicine, AlFaisal University, Riyadh, Saudi Arabia.
Firas GhomraouiUniversity at Buffalo- Catholic Health, Buffalo, NY, USA.
AbdulAziz AlansariDepartment of Pediatrics, King Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia.
Abdulaziz Al-HoshanCollege of Medicine, King Saud University, Riyadh, Saudi Arabia.
Sara AlKafBiostatistics, Epidemiology, and Scientific Computing Department, King Specialist Hospital and Research Center (KFSHRC), Riyadh. Saudi Arabia.
Wajeeh AldakheelDepartment of Pediatrics, King Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia.
King Faisal Specialist Hospital & Research Centre · SAAlfaisal University · SAKing Saud University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Internationally, Cystic fibrosis-associated liver disease (CFLD) is considered the third leading cause of death, following lung disease and transplantation complications. Aims: To identify the prevalence of CFLD in cystic fibrosis (CF) patients. Methodology: A retrospective chart review for all patients with CF liver disease from a tertiary care center. Result: A total of 341 CF patients were included. The mean age at the diagnosis of liver disease is 13.5 (7.6) years.The first elevated ALT was reported in 190/341 patients (56%), elevated AST in 124 patients (36%), elevated alkaline phosphatase (ALP) in 166 patients (49.1%), elevated GGT in 57 patients (23%), and elevated bilirubin in 24 patients (7%). There was an improvement of the liver enzyme values during the follow-up period, Conclusion: Patients with CF should be screened early for liver enzymes, and should undergo the US study to detect liver disease at early stages and to prevent its progression.

Indexed as

alanine aminotransferaseAST, aspartate aminotransferase APRialkaline phosphatase GGT, gamma glutamyl transpeptidase, LFTsAST to platelet ratio index FIB-4, Fibrosis-4 scoring system USCF, Cystic Fibrosis (CFTR) = Cystic Fibrosis Transmembrane Conductance Regulator Gene, Mutations.CFLDCFTRCholestasisCystic fibrosisCystic fibrosis liver diseaseLD, Liver diseaseALTLiver cirrhosis, ArabsLiver diseaseLiver function tests,INR, International normalized ratioUltrasound SD, Standard Deviation ALPUrsodeoxycholic acid

Identifiers

PMID35663788
PMCPMC9152554
OpenAlexW3173985665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.